8 
with proprietary information be fully apprised of the criminal 
sanctions for disclosure. 
Summary and Conclusions 
Dr. Fredrickson reported that NIH has received a request from the 
Eli Lilly Company to permit scale-up of recombinant DNA cultures to 150 
liters for production of insulin. RAC members are now reviewing that 
request, and it will be a key item on the agenda for their next meeting. 
Questions were asked about the company Genentech and whether it was in 
compliance with the Guidelines. Dr. Gartland noted that Genentech had 
proceeded to scale up under the old Guidelines and has not yet applied 
for the prior approval from NIH that the revised Guidelines require. 
Dr. Fredrickson pointed out that the supplement to the NIH Guidelines 
for the private sector would encourage industry to register activities 
and comply with the Guideline standards. He also observed, in response 
to Dr. Gryder's comments, that perhaps Commerce could be helpful in 
leading an industry survey to determine whether all private laboratories 
that conduct this research are complying with the Guidelines under the 
special supplement. 
Dr. Fredrickson thanked the Committee for its advice and consensus 
support for the voluntary approach. He promised to keep the members 
informed about the Department's review of this matter. Dr. Gartland had 
noted earlier that the RAC had voted 9 to 6, with 6 abstentions, in favor 
of mandatory compliance in the private sector. Dr. Fredrickson said 
that all views would be taken into account in drafting the preamble to 
[ 139 ] 
